U.S. markets close in 5 hours 2 minutes
  • S&P 500

    4,411.76
    -0.03 (-0.00%)
     
  • Dow 30

    35,027.35
    -34.20 (-0.10%)
     
  • Nasdaq

    14,838.42
    +1.43 (+0.01%)
     
  • Russell 2000

    2,223.34
    +13.69 (+0.62%)
     
  • Crude Oil

    71.50
    -0.57 (-0.79%)
     
  • Gold

    1,800.80
    -1.00 (-0.06%)
     
  • Silver

    25.28
    +0.05 (+0.19%)
     
  • EUR/USD

    1.1815
    +0.0044 (+0.38%)
     
  • 10-Yr Bond

    1.2700
    -0.0160 (-1.24%)
     
  • GBP/USD

    1.3827
    +0.0073 (+0.53%)
     
  • USD/JPY

    110.3160
    -0.1940 (-0.18%)
     
  • BTC-USD

    38,310.20
    +4,314.89 (+12.69%)
     
  • CMC Crypto 200

    916.69
    +1.20 (+0.13%)
     
  • FTSE 100

    7,017.91
    -9.67 (-0.14%)
     
  • Nikkei 225

    27,833.29
    +285.29 (+1.04%)
     

Bayer (BAYRY) Files Applications in US & EU for Cancer Treatment

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Bayer Aktiengesellschaft BAYRY announced that it has submitted a supplemental new drug application (sNDA) to the FDA, seeking approval of its marketed drug, Aliqopa (copanlisib) in combination with Roche’s RHHBY Rituxan (rituximab) for the treatment of patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (B-iNHL).

Simultaneously, Bayer also submitted a marketing authorization application or MAA to the European Medicines Agency (EMA), seeking approval of the novel combination of Aliqopa plus Rituxan for the treatment of relapsed marginal zone lymphoma (“MZL”), a subtype of iNHL.

Both U.S. and the EU filings were based on positive data from the double-blind, placebo-controlled phase III CHRONOS-3 study. The aim of the study was to check whether the combo of Aliqopa+Rituxan was superior to placebo plus rituximab in extending progression-free survival (“PFS”) in patients with relapsed iNHLafter one prior rituximab-containing therapy.

Data from the study showed that treatment with the combo of Aliqopa plus Rituxan (given intravenously) led to a significant improvement in PFS – the primary endpoint – as compared to the combination of rituximab and placebo.

Upon potential approval, the combo of Aliqopa plus Rituxan can provide a new treatment option for patients with different types of relapsed indolent non-Hodgkin’s lymphoma, thereby serving an area of unmet medical need.

Shares of Bayer have rallied 5.2% so far this year compared with the industry’s rise of 7%.

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research


We note that Aliqopa, a PI3K inhibitor, is already approved as a monotherapy for the treatment of relapsed follicular lymphoma (FL) in adult patients who have received at least two prior systemic therapiesin the United States, Israel and Taiwan. A potential label expansion will help the drug gain access to a broader patient population and consequently drive sales in the days ahead.

The FDA has granted Orphan Drug designation to Aliqopa for the treatment of FL and MZL as well as other types of lymphomas. The drug has received a breakthrough therapy designation in the United States and China for MZL.

Please note that the phase III CHRONOS-4 study is evaluating Aliqopa in combination with standard immunochemotherapy for the treatment of relapsed iNHL.

Zacks Rank & Other Stocks to Consider

Bayer currently carries a Zacks Rank #2 (Buy). Other stocks worth considering in the healthcare sector include Repligen Corporation RGEN and Bio-Techne Corporation TECH, both carrying the same Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Repligen’s earnings estimates have been revised 18.3% and 14.7% upward for 2021 and 2022, respectively, over the past 60 days. The stock has rallied 2.4% year to date.

Bio-Techne’s earnings estimates have been revised upward by 8.8% and 9.1% for 2021 and 2022, respectively, over the past 60 days. The stock has surged 38.6% year to date.

5 Stocks Set to Double

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Roche Holding AG (RHHBY) : Free Stock Analysis Report

Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report

Repligen Corporation (RGEN) : Free Stock Analysis Report

BioTechne Corp (TECH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research